|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Glutamine-β-cyclodextrin for targeted doxorubicin delivery to triple-negative breast cancer tumors via the transporter ASCT2.
|
31403158 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Seen as novel concepts in cancer development, ASCT2 and LAT transporters allow glutamine and EAAs to enter proliferating tumors as well as send a regulatory signal to mTOR.
|
30871192 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In adenocarcinomas, mRNA expression of glutamine transporter SLC1A5 correlated with tumor size (r(p) = 0.41, P = 0.005).
|
31668020 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In visual scoring, low, moderate, and high staining intensity of ASCT2 was observed in 4 (10%), 24 (60%), and 12 (30%) tumors, respectively.
|
31152256 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ASCT2ko 143B cells grew well in standard culture media, but ASCT2 was required for optimal growth at <0.5 mm glutamine, with tumor spheroid growth and monolayer migration of 143B ASCT2ko cells being strongly impaired at lower glutamine concentrations.
|
30635397 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SLC1a5 expression in the primary tumour and in the corresponding lymph node metastasis revealed a positive correlation (p = 0.005).
|
29455869 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Effects of ASCT2 and/or GS inhibitor on tumor growth were investigated in xenograft models.
|
29435734 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A new group of ASCT2 inhibitors, 2-amino-4-bis(aryloxybenzyl)aminobutanoic acids (AABA), were developed recently and shown to suppress tumor growth in preclinical <i>in vivo</i> models.
|
30072900 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although an <i>in vitro</i> growth-reduction phenotype was observed in A549-<i>ASCT2</i><sup>KO</sup> cells only, we found that genetic disruption of ASCT2 strongly decreased tumor growth in both cell lines.
|
29326164 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, the consequences of SLC1A5 knockdown on tumor growth and survival were also evaluated in vivo using mice carrying esophageal cancer xenografts.
|
30071532 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The mRNA expression levels of the amino acid transporters of system A (SLC38A1 and SLC38A2), system L (SLC7A5) and system ASC (SLC1A5) were higher in all eight tumors than in the normal lung, with widely varying expression patterns.
|
30334568 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor microarrays from patients with primary human colon cancers (n = 115) and CRC liver metastases (n = 111) were used to evaluate the prevalence of ASCT2, the primary glutamine transporter in oncology, by immunohistochemistry.
|
27770401 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Disease-free survival (DFS) in women with SLC1A5-positive non-serous tumors was 92% compared with of 66% in patients with SLC1A5-negative non-serous tumors (Log-rank = 15.343; P = 0.008).
|
28609484 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings thus elucidate a previously unreported mechanism responsible for ASCT2 deregulation in human cancers and identify ASCT2 as a critical downstream effector of miR-137, revealing a molecular link between DNA methylation, microRNA and tumor metabolism.
|
28692032 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, <i>in vivo</i> experiments indicated that suppression of SLC1A5 could inhibit relative volume of xenografted tumor.
|
29100325 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results highlight key differences in the ability of tumor and T cells to adapt to tryptophan starvation and provide important insights into the poor prognosis of tumors coexpressing IDO and SLC1A5.
|
27651314 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.
|
26455325 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
4-[(18)F]Fluoro-Gln uptake, but not 2-deoxy-2-[(18)F]fluoro-D-glucose, correlated with relative ASCT2 levels in xenograft tumors.
|
25971659 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Targeting SLC1A5 function decreased tumor growth in NSCLC xenografts.
|
25821004 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development.
|
25693838 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SLC1A5 expression levels were strongly associated with T stage of tumor (P < 0.05), and the tubular adenocarcinoma subtype (P < 0.001).
|
25337245 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The knockdown of the SLC1A5 high-affinity transporter for glutamine induces apoptosis and inhibits tumor formation in a mouse AML xenotransplantation model. l-asparaginase (l-ase) is an anticancer agent also harboring glutaminase activity.
|
24014241 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent studies considered both the importance of ASCT2 in tumour cell growth and the regulation of ASCT2 expression.
|
17127344 |
2007 |